Press release: Uppsala, March 25, 2022. Senzime announces today that the use of the TetraGraph system has been expanded to include small children with the CE-MDR approval of the new disposable and EMG-based TetraSens Pediatric.
Senzime's system for monitoring neuromuscular blockade during and after surgery – TetraGraph – has been CE marked since 2018 and is currently sold in 29 countries worldwide. The small and flexible TetraSens Pediatric broadens the target patient group for the TetraGraph system to also be used on young children.
Studies show that children face the same high risk of complications from the use of paralyzing drugs as adults. Infants and children have also shown large variations and prolonged duration of action after administration of NMB.
Pia Renaudin, CEO at Senzime, comments: "The use of paralyzing drugs in children is steadily increasing. Children are an extra sensitive patient group where it is more difficult to monitor neuromuscular activity during surgery. Our new disposable sensor TetraSens Pediatric helps to improve the monitoring of children during and after surgery.”